Company Overview
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.16.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +3.70% |
| 6 Months: | +37.52% |
| 3 Months: | +1.30% |
| 1 Month: | +12.72% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)50.40 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AURA Aura Biosciences, Inc. R2K | 7.00 | -4.09 | $723.71M | 0.00% | -74.67% | -95.57% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 29.04M | 28.61M | 27.91M | 27.24M | 34.87M |
| Operating Income | - | - | -3.63M | -5.93M | -8.80M | -8.89M | -12.81M | -13.82M | -16.05M | -19.44M | -20.28M | -20.49M | -22.31M | -22.76M | - | -29.04M | -28.61M | -27.91M | -27.24M | -34.87M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -28.74M | -28.33M | -27.63M | -26.96M | -34.59M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -27.46M | -26.97M | -26.10M | -25.54M | -33.67M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.00K | 48.00K | 26.00K | 15.00K | 11.00K |
| Net Income | -7.51M | -6.16M | -3.63M | -5.93M | -8.85M | -8.84M | -12.84M | -13.47M | -15.90M | -17.47M | -18.30M | -18.51M | -19.71M | -20.34M | - | -27.48M | -27.02M | -26.13M | -25.56M | -33.69M |
| Diluted EPS | - | - | - | - | -28.53 | -28.33 | -0.44 | -0.46 | -0.54 | -0.46 | -0.48 | -0.48 | -0.40 | -0.41 | -0.42 | -0.55 | -0.47 | -0.40 | - | -0.50 |
| R&D Expense | - | - | 2.85M | 4.18M | 6.63M | 6.37M | 8.28M | 9.51M | 11.29M | 14.40M | 15.12M | 15.43M | 17.05M | 16.88M | 17.04M | 23.34M | 22.88M | 22.18M | - | 27.96M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 60.30M | 84.99M | 96.12M | 112.79M |
| Operating Income | -22.21M | - | -60.30M | -84.99M | -96.12M | -112.79M |
| EBITDA | - | - | -59.12M | -83.70M | -94.89M | -111.66M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | - | -58.76M | -76.27M | -86.81M | -106.08M |
| Tax Provision | - | - | 0 | 137.00K | 112.00K | 108.00K |
| Net Income | -22.21M | - | -58.76M | -76.41M | -86.92M | -106.19M |
| Diluted EPS | - | - | -1.96 | -1.93 | -1.75 | -1.76 |
| R&D Expense | 18.04M | 25.16M | 42.24M | 65.23M | 73.30M | 90.30M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 22.10M | - | 223.94M | 255.07M | 182.50M | 169.43M |
| Current Assets | - | - | - | 196.70M | 231.79M | 160.62M | 149.74M |
| Cash & Equivalents | - | 17.39M | - | 121.58M | 41.06M | 31.69M | 59.52M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - |
| Total Liabilities | - | 2.74M | - | 28.35M | 29.23M | 30.53M | 32.52M |
| Current Liabilities | - | 2.66M | - | 10.46M | 12.36M | 14.91M | 18.38M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 20.86M | 19.56M | 18.77M | 17.38M |
| Total Equity | -87.41M | -108.71M | - | 195.58M | 225.85M | 151.97M | 136.91M |
| Shares Outstanding | - | - | - | 37.77M | 49.35M | 50.00M | 63.59M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -24.32M | - | -54.60M | -63.85M | -79.81M | -84.74M |
| Investing Cash Flow | -771.00K | - | -67.87M | -113.96M | 68.82M | 35.59M |
| Financing Cash Flow | 10.04M | - | 95.63M | 97.29M | 1.59M | 77.16M |
| Capital Expenditure | -771.00K | - | -1.09M | -709.00K | -1.25M | -447.00K |
| Free Cash Flow | -25.09M | - | -55.70M | -64.56M | -81.06M | -85.19M |
| Net Change in Cash | - | - | -26.84M | -80.52M | -9.39M | 28.01M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 20.4% | - | -30.0% | -33.8% | -57.2% | -77.6% |
| ROCE % | -114.2% | - | -28.2% | -35.0% | -57.4% | -74.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Matrix Capital Management Company LP | 6.70% | 6.92M | $53.79M |
| 2 | Frazier Life Sciences Management, L.P. | 4.93% | 5.10M | $39.63M |
| 3 | Adage Capital Partners GP L.L.C. | 4.72% | 4.88M | $37.93M |
| 4 | Long Focus Capital Management, LLC | 4.47% | 4.62M | $35.89M |
| 5 | Suvretta Capital Management, LLC | 4.23% | 4.37M | $33.98M |
| 6 | Blackrock Inc. | 3.47% | 3.59M | $27.87M |
| 7 | Medicxi Ventures Management (Jersey) Ltd | 2.94% | 3.04M | $23.62M |
| 8 | Vanguard Capital Management LLC | 2.17% | 2.24M | $17.43M |
| 9 | Nantahala Capital Management, LLC | 2.05% | 2.12M | $16.45M |
| 10 | Franklin Resources, Inc. | 2.00% | 2.07M | $16.11M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AURA
Aura Biosciences Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors
BOSTON, July 08, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of …
Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma
Enrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial Topline data from the 15-month primary endpoint expected in the second half of 2027 BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NA…
Aura Biosciences Gears Up for Bel-Sar Filing as Pivotal Eye Cancer Trial Advances
Aura Biosciences (NASDAQ:AURA) is shifting its focus toward regulatory preparation and commercialization planning as enrollment in its registrational CoMpass study of bel-sar in early choroidal melanoma nears completion, newly appointed CEO…
Aura Biosciences Highlights Bel-Sar Eye Cancer Strategy, Mid-Year Bladder Data
Aura Biosciences (NASDAQ:AURA) executives outlined the company’s strategy for its lead candidate bel-sar during a session at the H.C. Wainwright Connect Conference, emphasizing ocular oncology as the company’s initial development focus whil…
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today anno…
Aura Biosciences to Participate in Upcoming Investor Conferences
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its …
AURA — Frequently Asked Questions
What is the current share price of Aura Biosciences, Inc. (AURA)?
As of 2026-07-14 21:23 PDT, Aura Biosciences, Inc. (AURA) trades at $7.00 on NasdaqGM. Its 52-week range is $4.97 to $8.90.
What is the market capitalisation of AURA?
Aura Biosciences, Inc. (AURA) has a market capitalisation of $723.71M on NasdaqGM.
What is the P/E ratio of AURA?
AURA trades at a trailing price-to-earnings (P/E) ratio of -4.09. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 3.83.
What is the return on equity (ROE) of AURA?
AURA has a return on equity (ROE) of -95.57%. Its return on capital employed (ROCE) is -74.67%.
Is AURA a good stock to buy?
This page provides a data-driven analysis of Aura Biosciences, Inc. (AURA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.